加拿大Sophiris Bio  
Protox Therapeutics Inc. (温哥华，Vancouver)宣布公司就PRX302药物项目己向美国FDA提出摄护腺癌治疗药物的研究中新药申请(investigational new drug， IND)。一旦在FDA的IND案通过，公司预期便可以在下一年进行复发型部位固定摄护腺癌临床第一期测试。

2012年加拿大Protox Therapeutics Inc 改名为Sophiris Bio
 

Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).